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Abstract
Background: International sustainable development goals for the elimination of viral hepatitis as a public health
problem by 2030 highlight the need to optimize strategies for prevention, diagnosis and treatment of hepatitis B
virus (HBV) infection. An important priority for Africa is to have affordable, accessible and sustainable prevention of
mother to child transmission (PMTCT) programmes, delivering screening and treatment for antenatal women and
implementing timely administration of HBV vaccine for their babies.
Methods: We developed a decision-analytic model simulating 10,000 singleton pregnancies to assess the cost-
effectiveness of three possible strategies for deployment of tenofovir in pregnancy, in combination with routine
infant vaccination: S1: no screening nor antiviral therapy; S2: screening and antiviral prophylaxis for all women who
test HBsAg-positive; S3: screening for HBsAg, followed by HBeAg testing and antiviral prophylaxis for women who
are HBsAg-positive and HBeAg-positive. Our outcome was cost per infant HBV infection avoided and the analysis
followed a healthcare perspective.
Results: Based on 10,000 pregnancies, S1 predicts 45 infants would be HBV-infected at six months of age,
compared to 21 and 28 infants in S2 and S3, respectively. Relative to S1, S2 had an incremental cost of $3940 per
infection avoided. S3 led to more infections and higher costs.
Conclusion: Given the long-term health burden for individuals and economic burden for society associated with
chronic HBV infection, screening pregnant women and providing tenofovir for all who test HBsAg+ may be a cost-
effective strategy for South Africa and other low/middle income settings.
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Background
In order to meet targets set by international Sustainable
Development Goals for the elimination of Hepatitis B
Virus (HBV) infection as a public health problem by the
year 2030 [1], enhanced efforts are required to reduce
the incidence of new cases. Strategies that set out to
achieve this need to be carefully evaluated, both on the
grounds of effect on individual and population health,
and also based on value for money. HBV infection is en-
demic in many low/middle income settings [2–4], where
economic evaluations are particularly important for inform-
ing the appropriate deployment of limited health care
resources.
Prevention of mother to child transmission (PMTCT)
is a cornerstone of HBV elimination strategies. Reducing
vertical transmission is crucial to population health, as
up to 90% of neonates who are exposed to HBV
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perinatally become chronic carriers, compared to only
5% of those exposed as adults [5, 6]. Current recom-
mended practice includes screening antenatal women
for infection using hepatitis B surface antigen (HBsAg),
and risk-stratification based on further laboratory tests
for hepatitis B e-Antigen (HBeAg) and/or HBV DNA
viral load (VL), which can be used to stratify the risk of
vertical transmission. PMTCT guidelines suggest admin-
istering a three dose HBV vaccine to all infants with the
first dose administered within 24 h of birth and two
other doses provided at 6 and 10 weeks respectively, as
well as administering hepatitis B immunoglobulin
(HBIg) to high risk babies in the first day of life [7, 8].
Together, these strategies reduce the rate of vertical
transmission by 85–95% [9], representing a crucial com-
ponent of efforts towards HBV elimination [10–12].
However, breakthrough transmission can occur, espe-
cially among mothers with high HBV VL [13], in settings
where the first dose of vaccine is delayed, and where
HBIg is not available. The use of antivirals during preg-
nancy can therefore be included as an additional meas-
ure to decrease transmission risk [14]. Tenofovir
disoproxil fumarate (TDF) has a track record of safety
and efficacy in this setting [15, 16], and is included in
some guidelines for HBV PMTCT [8, 17].
HBV is endemic in Africa, with a prevalence of > 8%
in many populations [18, 19]. The risk of MTCT in this
continent is enhanced by lack of routine antenatal
screening [20, 21], deliveries taking place outside health-
care facilities, delayed first dose of HBV vaccine until
age six weeks by many vaccine programmes, and inad-
equate access to TDF and HBIg [18, 20]. A meta-
analysis of data from sub-Saharan Africa (sSA) demon-
strated a perinatal transmission rate of 38% among
women who tested positive for HBsAg and HBeAg, in
the absence of any PMTCT interventions [22]. An im-
portant priority for Africa is to have affordable, access-
ible and sustainable PMTCT programmes that deliver
screening and treatment for antenatal mothers, and
oversee timely administration of HBV birth vaccine for
their babies [10, 23]. Providing antiviral treatment for
HBV PMTCT relies on HBV diagnosis, but currently
there is not widespread access to laboratory-based assays
for HBsAg, HBeAg and HBV DNA viral load, and many
antenatal programmes do not provide routine HBV
screening.
In order to identify the most cost-effective approach to
HBV PMTCT we have evaluated antenatal screening for
HBV infection using standard laboratory assays for HBsAg
and treating HBsAg-positive women with TDF, based on
South Africa as a model situation. In recognising the im-
portant role that lateral flow assays can play in point of
care testing (POCT) for HBsAg, we also assessed the cost
effectiveness of this approach to diagnostic screening [21,
24]. In South Africa, the majority of pregnant women are
not routinely screened for HBV infection, vaccination be-
gins at six weeks of age and HBIg is not available. Model-
ling the cost-effectiveness of HBV PMTCT interventions
allows for a combined analysis of clinical outcomes and
potential budget impact, which is fundamental to inform
financial investment in HBV elimination programmes in
sSA countries.
Methods
Target population and study perspective
We used a hypothetical cohort of 10,000 pregnant South
African women to evaluate the cost-effectiveness of
three different strategies for antiviral therapy with TDF:
Strategy 1 (S1): No TDF prophylaxis
No pregnant woman is screened for HBsAg and there-
fore no HBV treatment is given perinatally. To date, this
is the situation in many resource-limited settings in sSA.
Strategy 2 (S2): Screening and TDF prophylaxis for all
women who test HBsAg positive
All pregnant women are screened for HBsAg; those who
test positive are treated with TDF from 28 weeks gesta-
tion to four weeks post-partum.
Strategy 3 (S3): Screening and TDF prophylaxis for women
who are both HBsAg positive and HBeAg positive
All pregnant women are screened for HBsAg; those who
test positive are then screened for HBeAg. Only those
who are HBeAg positive are treated with TDF from 28
weeks gestation to four weeks post-partum.
We populated our model with data using a healthcare
system perspective and therefore only considered costs
that would be directly incurred by the Department of
Health (DOH). These costs relate to screening and treat-
ment of HBV infection during pregnancy. Individual pa-
tient information was not included in this analysis.
Ethics approval was not required for this study.
Assumptions
For the purposes of this analysis, we made a number of
modelling assumptions:
 All pregnancies are singleton and result in the
delivery of a live infant;
 All infants receive HBV vaccine at 6, 10 and 14
weeks, as per standard practice to date in South
Africa. Even for babies born to mothers who are
HBsAg+, birth dose vaccination is not offered within
24 h (due to lack of maternal screening);
 HBV screening uptake is 100% among antenatal
women;
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 HBsAg and HBeAg are tested using laboratory
assays which are 100% sensitive and specific;
 Infants born to mothers who were HBsAg negative
were assumed also to be HBsAg negative;
 We made assumptions around our point estimates
due to lack of data.
Theoretic modelling approach
A decision tree providing a framework for comparison
of the three strategies is shown in Fig. 1. The decision
tree considers the period covering weeks 28 through 40
of gestation up to six months post-partum. Model struc-
ture was the same for all strategies. HBsAg-positive
mothers had a defined probability of being HBeAg posi-
tive or negative; these probabilities were the same for all
strategies. Children whose mothers were HBsAg positive
had a probability of being HBsAg positive themselves (i.e.
a case of MTCT). This probability depended on whether
the mother was also HBeAg positive and whether antiviral
prophylaxis was received by the mother during pregnancy,
which varied between strategies.
Measurement of effectiveness
Table 1 shows parameters used in our model. We
searched the published literature, and identified four
studies from within the last six years that reported the
prevalence of HBV infection among pregnant women in
South Africa [21, 25–27]. To calculate prevalence of
HBV infection, we combined the total number of
women from each study who tested HBsAg-positive and
divided these by the total number of individuals included
in these cohorts. From these pooled data, the overall
prevalence of HBsAg among pregnant women was 3.6%
(129/3614). HBeAg status was reported for 126 of these
129; the prevalence of HBeAg among HBsAg+ women
was 29/126 (23%).
We derived point estimates for perinatal transmission
with and without antiviral therapy during pregnancy
from a published systematic review and a meta-analysis
[15, 22]. In the absence of intervention (HBV vaccin-
ation, HBIg and/or antiviral therapy), the perinatal trans-
mission rate for HBsAg+/HBeAg+ mothers in sSA was
estimated at 38%, and for HBsAg+/HBeAg- mothers was
4.8% [22]. Due to lack of data, we used these estimates
in our model, although we assumed that infants were
vaccinated starting at the age of six weeks.
There is only one randomised control trial that examines
the efficacy of TDF on HBV PMTCT, in which perinatal
TDF reduced the risk of infant HBsAg seropositivity by
71% [14]. However, data from a systematic review and
meta-analysis estimate this figure as 77% [15]. We reduced
the perinatal transmission rate for women receiving no
Fig. 1 Decision tree showing possible approaches to evaluation of HBV infection in a simulated cohort of 10,000 antenatal women, and in their
infants at age six months. P1 is the probability of women testing positive for HBsAg; P2 is the probability of women who are positive for HBsAg
also testing positive for HBeAg; P3 is the probability of infants born to HBsAg+/HBeAg+ mothers testing HBsAg+ at 6 months of age; P4 is the
probability of infants born to HBsAg+/HBeAg- mothers testing HBsAg+ at 6 months of age. HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B
e antigen; TDF: Tenofovir disoproxil fumarate
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TDF by 71% to obtain a point estimate for perinatal trans-
mission rate for those receiving TDF peripartum prophy-
laxis; these were estimated at 11.1% for HBeAg-positive
women and 1.4% for HBeAg-negative women. We
accounted for uncertainty around point estimates, as the
original study was conducted in China and with a different
protocol (combining TDF during pregnancy in combin-
ation with birth dose vaccine and HBIg).
Due to lack of data on HBV antiviral adherence rates
among pregnant women in sSA, we used HIV antiretroviral
adherence rate among women during and after pregnancy,
obtained from a published systematic literature review
which included studies from low-income, middle-income,
and high-income countries [28]; this is estimated at 73.5%.
We incorporated an expected adherence of 73.5% into the
model, assuming that those mothers who didn’t adhere
would incur the full cost of treatment but would have the
same probability of transmission as untreated women.
Outcomes
Our outcome was the cost per HBV infection avoided
among infants at the age of six months. This outcome was
selected because it is quantifiable, clinically relevant and
could be easily compared between strategies.
Estimating costs
We derived costs for laboratory assays for HBsAg and
HBeAg, and POCT, from a 2015 price list produced by Na-
tional Health Laboratory Services (NHLS) and DOH, South
Africa [29]. We used the cost of TDF from International
Medical products price guide for year 2015 [30]. We con-
verted the price of HBsAg laboratory assay (ZAR108.86),
HBsAg POCT (ZAR18), HBeAg laboratory assay
(ZAR108.86) and HBV DNA test (R1173.32) from South
African Rand (ZAR) to US Dollars (USD); 1 ZAR =
0.083 USD as at 1st May 2018. HBsAg screening cost
applied to all women in S2 and S3; HBeAg screening
costs applied to women who tested positive for
HBsAg in S3. TDF costs applied to all women who
tested positive for HBsAg in S2, and women who
tested positive for both HBsAg and HBeAg in S3.
Scenario analysis
We assessed the impact of three additional scenarios, es-
timating the number of MTCT cases, costs and incre-
mental cost per infection avoided in each case:
(i.) Antenatal screening for HBV infection using a rapid
point of care test (POCT)
Table 1 Parameters used for input into a model of cost-effectiveness of tenofovir for PMTCT in South Africa, based on a simulated
cohort of 10,000 antenatal women and their babies
Parameter Point estimate Uncertainty (Lower
bound - Upper bound)
Source
(references)
p1: Probability of mother being HBsAg+ 3.6% 3.1–7.4%b [21, 25–27]
p2: Probability of mother who is HBsAg+ being HBeAg+ 23% 16.7–42.9%b [21, 25–27]
p3: Probability of mother who is HBsAg+ and HBeAg+ having
child who is HBsAg+ (no PMTCT)
38.3% 7.0–74.4%b [22]
p4: Probability of mother who is HBsAg+ and HBeAg- having
child who is HBsAg+ (no PMTCT)
4.8% 0.1–13.3%b [22]
Relative risk reduction (efficacy) of TDF 71% 26–89% [15]
Antiviral adherence 73.5% 69.3–77.5% [28]
S2: Cost of diagnostics: laboratory test for HBsAg $9.1 per mother [29]
S3: Cost of diagnostics: laboratory test for HBsAg and HBeAg $9.1 per mother (HBsAg test) + $9.1 for
HBsAg+ mother
(HBeAg test)
[29]
S2: Cost of diagnostics: POCT for HBsAg $2 * all mothers [29]
S3: Cost of diagnostics: POCT for HBsAg+ and laboratory test for
HBeAg+
$2 * for all mothers (HBsAg test) + $ 9.1 *
for all HBsAg+ mothers (HBeAg test)
[29]
Treatment cost: monthly cost of TDF, applied to all HBsAg+
women (S2) or only to HBsAg+/HBeAg+ women (S3)
$2.48a/month [30]
POCT sensitivity 97.6% [21]
Estimated relative risk reduction (efficacy) of TDF when
combined with birth dose vaccine and HBIg
90% 85–95% [9]
Prevalence of TDF resistance 0.08% [31]
a To cover the cost of TDF treatment from 28 weeks’ gestation to 4 weeks post-delivery, we multiplied the cost for one month by four. A triangular distribution
allows for uncertainty in all probabilities (except cost which we assume is fixed)
b The uncertainty values for p1 and p2 were derived from studies that had the lowest and highest HBsAg prevalence rates, representing lower and higher bounds
respectively; whereas uncertainly values for P3 and P4 were from 95% confidence intervals around the mean value
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We estimated the cost-effectiveness of using a POCT
for HBsAg screening, based on a POCT sensitivity of
97.6% and specificity of 100%, compared to laboratory
ELISA HBsAg testing as the gold standard [21]. We in-
corporated this into the model by reassigning the pro-
portion of women expected to test falsely HBsAg-
negative using a POCT into the untreated group and re-
moving the cost of TDF treatment for these individuals.
(ii.)Recommended PMTCT guidelines: Universal birth
dose vaccination and HBIg
To assess the cost-effectiveness of antenatal screening
and treating of HBsAg-positive women with TDF in
combination with universal birth dose vaccine and HBIg,
we estimated that perinatal transmission rate will be re-
duced by 90% [9]. To incorporate the impact of TDF in
our cohort, we therefore reduced the perinatal transmis-
sion rate by 90%; MTCT rates were thus estimated for
HBsAg+ women who are HBeAg+ and HBeAg- at 3.8
and 0.48% respectively.
(iii.) HBV resistance to TDF
In order to consider the possible impact of drug resist-
ance on the PMTCT strategies outlined here, we esti-
mated the prevalence of TDF resistance based on HBV
sequences retrieved from the HBV database (https://
hbvdb.ibcp.fr/HBVdb/) [32] accessed on the 18th April
2018. The numerator was the total number of sequences
with mutations associated with reduced sensitivity/resist-
ance to TDF (rtA194T, rtN236T, rtS78T) [31, 33], and
the denominator was the total number of sequences
available in the database (49/6287, 0.8%). This preva-
lence was incorporated into the model by re-assigning
0.8% of those receiving TDF into the untreated category
(as although they receive the drug, resistance would ren-
der this functionally equivalent to no treatment).
Analytic methods and definitions
We used the following definitions:
 A strategy was ‘dominated’ if it had a higher
expected cost and more predicted cases of HBV
MTCT compared to an alternative strategy.
 The incremental cost per HBV infection avoided
was determined by dividing the difference in cost
between two strategies over the difference in
number of infections.
We compared the strategies by first applying decision
rules to eliminate any strategies which were dominated
by others, and then estimated the incremental cost per
infection avoided for the remaining strategies.
The combined effect of uncertainty in probability
estimates was assessed using probabilistic sensitivity
analysis, with 1000 Monte Carlo simulations run. We
used triangular distributions to approximate Beta distri-
butions for probabilities. Triangular distributions
required a lower and upper bound, with the peak taken
as the expected (mean) value. The impact of uncertainty
is shown on a cost-effectiveness plane, where sets of
incremental costs and number of infections avoided are
plotted for S2 and S3, relative to S1.
Standardised criteria
Our analysis conforms to the standardised criteria for eco-
nomic evaluations of health interventions. Our CHEERS
checklist can be reviewed as Additional file 1: Table S1
on-line: https://doi.org/10.6084/m9.figshare.7265582.v2
Results
Cost-effectiveness of strategies for HBV PMTCT under
base case assumptions
We modelled three different approaches to peri-partum
TDF prophylaxis: S1: no screening or antiviral therapy;
S2: screening and antiviral prophylaxis for all women
who test HBsAg-positive; S3: screening for HBsAg,
followed by HBeAg testing and antiviral prophylaxis for
women who are HBsAg-positive and HBeAg-positive
(Fig. 1). Based on the simulated scenario of 10,000
singleton pregnancies in South Africa, with no antiviral
therapy for HBV PMTCT (S1), and using a laboratory-
based assay for HBsAg detection, our model predicts 45
infants would be infected with HBV at age six months
(incidence 0.45%). If antiviral prophylaxis interventions
are employed based on S2 and S3, this would be reduced
to 21 and 28 infants, (incidence 0.21 and 0.28%) respect-
ively, at the cost of deploying the intervention for the
whole population. Compared to S1, cost per infection
avoided was $3940 for S2, lower than for S3 which
would be more costly and avoid a lower number of in-
fections (Table 2; Fig. 2).
Cost-effectiveness of strategies for HBV PMTCT under
scenario analyses
(i.) Antenatal screening for HBV infection using a rapid
point of care test (POCT)
POCT for HBsAg was cheaper in comparison to
laboratory-based HBsAg assay (for S2: POCT $23,401 vs
lab test $94,571 and for S3: POCT $23,979 vs lab test
$95,097); (Tables 2 and 3). Based on reasonable assump-
tions about sensitivity of HBsAg detection via laboratory
ELISA vs POCT (100 and 97.6%, respectively [21]), from
our simulated cohort, laboratory testing would detect all
maternal HBV infections (n = 360 in our hypothetical
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cohort of 10,000), while the POCT approach would de-
tect 351 and miss nine cases of infection. This loss of
sensitivity translates into a marginal decrease in cost-
effectiveness: the incremental cost per infection avoided
is estimated at $1017 compared to $978 if the test had
100% sensitivity.
(ii.)Recommended PMTCT guidelines: Universal birth
dose vaccination and HBIg
Incorporating universal birth dose vaccination and
HBIg into our model, reduced the number of infants in-
fected at six months and cost per infection avoided (S2:
15 infants infected; S3: 24 infants infected; and cost per
infection avoided: $3152), (Table 3), compared to when
PMTCT intervention includes only TDF and HBV vac-
cination beginning at six weeks, (S2: 21 infants infected;
S3: 28 infants infected; and cost per infection avoided:
$3940) (Table 2).
(iii.) HBV resistance to TDF
When we accounted for potential HBV resistance to
TDF, based on a prevalence of drug resistance estimated
at 0.8% [31], there was no change in incremental cost
per infection avoided in S2.
Data visualisation
We reproduced our decision model as an R Shiny appli-
cation (source code available here: https://github.com/
edward-burn/PMTCT-HBV-cost-effectiveness-analysis).
This can be used to estimate cost-effectiveness of our
three strategies using different input parameters. This
will allow the analysis to be re-run for the same com-
parison of strategies but in contexts where the epidemi-
ology of HBV infection, and costs of interventions, are
different.
Discussion
Antenatal screening and treating of pregnant women for
HBV is not routinely performed in many settings in sSA,
despite the high population prevalence of HBV [21, 25–27].
In resource-limited settings, screening and providing
prophylactic TDF for all pregnant women who are HBsAg
positive may be the most efficient strategy, especially when
using a POCT. These results are derived from a theoretical
model, and careful consideration is needed for application
to different real world settings.
Based on existing data for South Africa, screening and
treating women with TDF from 28 weeks of pregnancy
to four weeks post-delivery reduces the number of in-
fants with HBV at six months. Previous studies have also
reported on the safety and effectiveness of TDF for HBV
PMTCT [15, 16]. There is evidence for the cost-
effectiveness of combining antiviral therapy during preg-
nancy with HBV immunoprophylaxis, as highlighted by
a systematic review and meta-analysis carried out in
China [35] and a study conducted in North America
Table 2 Cost-effectiveness results under base case assumptions for screening for HBsAg using laboratory-based assay on a
simulated birth cohort of 10,000 live singleton infants
Strategy Number of infant HBV
infectionsa (95% CI)
Cost of deploying the intervention for the
whole populationb (n = 10,000) in USD (95% CI)
Incremental cost per infection
avoided (USD)
S1 45 (29–121) 0 –
S2 21 (14–69) 94,571 (94,487 - 95,509) 3940 (compared to strategy S1)
S3 28 (19–76) 95,097 (94,980 - 97,244) Dominatedc (by strategy S2)
a World Health Organisation (WHO) criteria for HBV elimination states an aim of 90% reduction in new chronic infection [1]
b Price of TDF estimated at $2.48/month for strategies S2 and S3 [30]
c S3 is dominated due to both higher costs and higher infections compared to S2
CI = confidence interval
Fig. 2 Cost-effectiveness (CE) plane for HBsAg using laboratory assay
in a simulated cohort of 10,000 antenatal women. S2: All pregnant
women are screened for HBsAg; those who test positive are treated
with TDF from 28 weeks’ gestation to 4 weeks post-partum. S3: All
pregnant women are screened for HBsAg, those who test positive
are screened for HBeAg. Only those who are HBeAg positive are
treated with TDF from 28 weeks’ gestation to 4 weeks post-partum
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[36]. Interestingly, a recent study in Thailand conflicted
with these findings by reporting no significant benefit of
maternal TDF for PMTCT [37]. The lack of benefit from
TDF in this case may be because all infants in the Thai
study received birth dose of both HBIg and HBV
vaccine, followed by four additional doses of HBV
vaccine; this enhanced immunoprophylaxis probably
accounts for the low rate of HBV transmission even
among mothers who did not receive TDF. However, it is
difficult to apply any of these findings to sSA, which dif-
fers in having limited (or no) access to HBIg, gaps in
vaccine coverage, and delays in the first dose of HBV
vaccine (in South Africa to date, as in many other set-
tings in sSA, this has been until age six weeks) [20].
In this study, we provide a head-to-head economic
analysis of simulated screening for HBsAg alone vs. use
of HBsAg in combination with risk stratification using
HBeAg. Limited resources and infrastructure have im-
peded antenatal diagnosis and treatment of HBV [34,
39], and stratification of HBsAg-positive antenatal
women with HBV DNA level and/or HBeAg to deter-
mine eligibility for TDF incurs further cost. Given that
TDF is becoming more accessible for HBV treatment in
Africa [12, 40], and has a well-established safety record
as a result of antenatal use in HIV infection, treating all
HBsAg positive women should be safe and practical, as
well as cost-effective. As this option is simple to imple-
ment, it is therefore also most likely to be successful.
Given the high prevalence of HBV in Africa [2, 3],
POCT is an appealing route to increasing diagnosis and
therefore access to treatment. Although POCT proves
advantageous on cost grounds, it is less sensitive than la-
boratory assays. Furthermore, laboratory support
remains key for monitoring response to treatment, iden-
tifying and monitoring drug resistance, and evaluating
prognosis.
There is a potential risk that increasing population ex-
posure to TDF may increase selection of resistance [38].
However, the genetic barrier to TDF resistance is high,
and more data are needed to determine the prevalence
and clinical significance of putative drug resistance mu-
tations. When accounting for an estimated background
rate of HBV resistance to TDF, we show no change in
the cost per infection avoided. While we recognise that
TDF resistance is not currently a significant clinical con-
cern, the modelling approach we have developed allows
drug resistance to be factored in.
Despite the potential for increased risk of HBV MTCT
in HIV/HBV coinfection there is evidence to show that
HIV has very little effect on HBV interventions [41].
Since HIV guidelines now recommend commencement
of antiretroviral treatment as soon as HIV diagnosis is
made [42], the impact of HIV on HBV PMTCT is fur-
ther reduced.
We used a simple model with only a single outcome
measure, thus overlooking other possible risks/benefits
of antiviral therapy, including side-effects, drug interac-
tions, and rebound hepatitis after treatment cessation.
However, extensive experience has led to the inclusion
of TDF in first-line regimens for HIV, including in preg-
nant women. Our base values were obtained from pub-
lished literature, but there are limited data for HBV
Table 3 Cost-effectiveness results of different PMTCT strategies under scenario analyses on a simulated birth cohort of 10,000 live
singleton infants
Strategy Number of infant HBV
infectionsa (95% CI)
Cost of deploying the intervention for the
whole population (n = 10,000) in USD (95% CI)
Incremental cost per infection
avoided (USD)
Scenario analysis (i): POCT testing
S1 45 (28–119) 0
S2b 22 (14–73) 23,401 (23,330 – 24,243) 1017 (compared to strategy S1)
S3b 28 (19–78) 23,979 (23,882 – 25,937) Dominatedc (by strategy S2)
Scenario analysis (ii): Universal birth dose vaccination
S1 45 (28–123) 0 –
S2d 15 (11–82) 94,571 (94,489 - 95,503) 3152 (compared to strategy S1)
S3d 24 (17–84) 95, 097 (94,981 – 97,291) Dominatedc (by strategy S2)
Scenario analysis (iii): TDF resistance
S1 45 (29–119) 0 –
S2d 21 (14–71) 94,571 (94,496 – 95,515) 3940 (compared to strategy S1)
S3d 28 (18–79) 95,097 (94,980 – 97,252) Dominatedc (by strategy S2)
a World Health Organisation (WHO) criteria for HBV elimination states an aim of 90% reduction in new chronic infection [1]
b Price of TDF estimated at $2.42/month for strategies S2 and S3 when using POCT
c S3 is dominated due to both higher costs and higher infections compared to S2
d Price of TDF estimated at $2.48/month for strategies S2 and S3 [30]
CI = confidence interval
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epidemiology and transmission for most African popula-
tions; we have acknowledged the lack of certainty
around certain parameters by including confidence in-
tervals. HBV DNA testing is the gold standard approach
to HBV diagnosis, but is often not available in resource-
limited settings; we therefore used HBeAg status as a sur-
rogate marker to represent infectivity and high VL and as-
sumed 100% sensitivity for laboratory-based assays for
HBsAg and HBeAg. This does not account for occult in-
fection and other false negatives and may lead to an over-
estimation of the cost-effectiveness of maternal TDF.
The assumption that the first dose of HBV vaccine is
delayed until age six weeks is an over-simplification: if
birth dose vaccine is given more widely or targeted for
infants born to HBsAg-positive mothers, more new in-
fections will be averted.
We used data for South Africa, but recognise that
HBV prevalence is substantially higher in other sSA set-
tings (frequently reported at ≥8%, the WHO threshold
for high endemicity [18, 19]) and this may influence the
cost-effectiveness of proposed interventions. The low
prevalence rate that we derived from South Africa may
be a reflection that many antenatal women themselves
received HBV vaccination as infants (if born after 1995).
To facilitate cost-effectiveness simulations in other set-
tings where antenatal HBV prevalence might be higher,
we have provided an on-line interactive tool.
The findings of this study are applicable to settings
where the cost of screening and treatment is publicly
funded; in situations where individuals meet the cost of
their own screening and treatment, our results cannot be
applied to informing public health strategy. Our analysis
did not consider the need for healthcare and laboratory
infrastructure to support our proposed interventions,
costs of monitoring pregnant women during TDF treat-
ment, costs for clinical visits and counselling for mothers
testing HBsAg positive, leading to an underestimation of
the total costs included in providing robust PMTCT.
However, this is offset by the potentially very substantial
lifelong costs of chronic HBV infection, both to individ-
uals and to society, arising from morbidity and mortality
typically affecting young and middle-aged adults [4, 5, 34,
43]. This is difficult to quantify but leads to a substantial
burden of chronic disease with economic consequences
for the health-care system, as well as imposing financial
consequences on families and society [34].
Conclusion
We have developed a simple, theoretical model that al-
lows us to estimate the impact of providing TDF to
antenatal women in a lower/middle income country set-
ting, either based on HBsAg status alone, or incorporat-
ing risk-stratification with HBeAg. These strategies
reflect safe, practical interventions that could reasonably
be deployed in many settings. There remains an urgent
need for more data to underpin the relevant epidemi-
ology, risks of MTCT, and relative benefits of different
interventions in settings across sSA. In order to drive
progress towards 2030 elimination targets, sustained
investment is required to drive improvements in clinical
services, provide universal access to antenatal screening,
improve education of the public and health-care
workers, and underpin robust deployment of PMTCT
interventions including vaccination and TDF therapy.
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